NeoGenomics (NEO) AI Stock Analysis

• Market Cap: $1.35B
• Dividend Yield: N/A
• Average Volume (3M): 4.53M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 10.10%
• EPS Growth: -44.29%
• Country: US
• Employees: 2,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 129,387,800
• 10 Day Avg. Volume: 4,140,149
• 30 Day Avg. Volume: 4,526,006
• PEG Ratio: 0.46
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.63
• P/FCF Ratio: -12.26
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 1.75
• Enterprise Value/Gross Profit: 4.02
• Enterprise Value/Ebitda: -36.68
• 1Y Price Target: $13.14
• Price Target Upside: 26.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.1
• Revenue Forecast (FY): $725.03M

• Rating: 53 Neutral
• Price Target: $10.00 ▼(-3.85% Downside)

NeoGenomics shows strong clinical revenue growth and positive technical momentum, but significant challenges in profitability and valuation weigh heavily on the overall score. The earnings call provided some optimism with successful acquisitions and favorable legal outcomes, yet ongoing issues in nonclinical revenue and profitability remain a concern.

Positive Factors

Clinical Revenue Growth

Strong clinical revenue growth driven by increased test volumes and pricing highlights NeoGenomics' robust market position in oncology diagnostics.

Successful Acquisition

The Pathline acquisition enhances service capabilities and market reach, potentially boosting profitability and competitive positioning.

Favorable Legal Outcome

The legal victory enables the launch of RaDaR ST, expanding product offerings and potentially increasing future revenue streams.

Negative Factors

Profitability Challenges

Persistent profitability issues, with negative margins, indicate ongoing challenges in cost management and financial sustainability.

Cash Flow Struggles

Negative cash flow highlights inefficiencies in operations, potentially limiting investment in growth and innovation.

Decline in Nonclinical Revenue

A significant drop in nonclinical revenue, especially in pharma, suggests challenges in diversifying income streams and market demand.

NeoGenomics Business Overview & Revenue Model

Company Description

NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing and diagnostic services. The company operates primarily in the healthcare sector, specializing in advanced genomic testing for oncology. NeoGenomics offers a comprehensive range of services, including molecular testing, hematopathology, and clinical trial services, aimed at improving cancer patient outcomes through precise and personalized treatment options.

How the Company Makes Money

NeoGenomics generates revenue primarily through its laboratory services, which include various cancer testing and diagnostic assays. The company charges healthcare providers, including hospitals and oncologists, for each test conducted. Key revenue streams include molecular testing, which encompasses a wide array of genetic and genomic tests, and anatomic pathology services. Additionally, NeoGenomics collaborates with pharmaceutical companies for clinical trial testing, providing another revenue source through partnerships. The company's focus on expanding its test menu and enhancing its capabilities in precision medicine contributes to its earnings, along with its strategic partnerships with healthcare institutions and research organizations.

NeoGenomics Financial Statement Overview

Summary

NeoGenomics is experiencing revenue growth but continues to face significant profitability and cash flow challenges. While leverage has improved, the company needs to address its negative margins and cash flow issues to enhance financial stability and investor confidence.

Income Statement

NeoGenomics has shown some revenue growth, with a TTM increase of 2.9%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is moderate at 43.5% TTM, but the consistent negative net income highlights ongoing challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.49 TTM, indicating better leverage management compared to previous years. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio is stable, suggesting a balanced asset structure, but profitability issues persist.

Cash Flow

NeoGenomics faces challenges in cash flow management, with negative free cash flow and a declining free cash flow growth rate. The operating cash flow to net income ratio is low, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow struggles.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	709.16M	660.57M	591.64M	509.73M	484.33M	444.45M
Gross Profit	308.21M	290.10M	244.60M	187.90M	187.06M	185.89M
EBITDA	-33.74M	-1.51M	-17.61M	-82.33M	-65.40M	34.85M
Net Income	-113.47M	-78.73M	-87.97M	-144.25M	-8.35M	4.17M
Balance Sheet
Total Assets	1.37B	1.64B	1.68B	1.74B	1.87B	988.33M
Cash, Cash Equivalents and Short-Term Investments	164.12M	386.84M	415.20M	437.99M	515.39M	296.26M
Total Debt	410.31M	605.33M	611.68M	610.93M	612.79M	218.22M
Total Liabilities	438.62M	735.70M	739.69M	742.01M	761.50M	294.04M
Stockholders Equity	838.29M	902.34M	941.54M	998.02M	1.11B	694.29M
Cash Flow
Free Cash Flow	-17.05M	-34.04M	-30.70M	-96.88M	-90.86M	-27.64M
Operating Cash Flow	13.69M	7.02M	-1.95M	-65.99M	-26.72M	1.46M
Investing Cash Flow	-11.50M	12.86M	76.71M	517.00K	-632.37M	-159.44M
Financing Cash Flow	-200.03M	4.65M	4.55M	11.83M	725.28M	235.60M

NeoGenomics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEO, the sentiment is Positive. The current price of 10.4 is above the 20-day moving average (MA) of 10.11, above the 50-day MA of 9.05, and above the 200-day MA of 8.78, indicating a neutral trend. The MACD of 0.35 indicates Positive momentum. The RSI at 55.67 is Neutral, neither overbought nor oversold. The STOCH value of 44.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NEO.

NeoGenomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRAL	64 Neutral	$3.05B	―	-17.68%	―	22.37%	86.08%
CSTL	62 Neutral	$979.86M	―	-2.69%	―	10.15%	-295.52%
FLGT	57 Neutral	$697.27M	―	-4.54%	―	4.31%	69.57%
NEO	53 Neutral	$1.35B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$613.35M	―	-72.52%	―	0.21%	-233.51%
OPK	50 Neutral	$1.07B	-5.64	-13.32%	―	-9.75%	-31.28%

NeoGenomics Corporate Events

NeoGenomics Reports Strong Revenue Growth Amid Rising Losses

NeoGenomics, Inc. is a leading cancer diagnostics company specializing in oncology-focused testing services, providing comprehensive diagnostic solutions to oncologists, pathologists, and healthcare institutions across the United States and the United Kingdom.

NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges

NeoGenomics Inc. recently held its earnings call, revealing a strong performance in its clinical segment, marked by significant volume and revenue growth. The call highlighted successful acquisitions and favorable legal outcomes, although challenges persist in the nonclinical revenue sector, particularly in the pharma segment, which are expected to continue into 2026.

NeoGenomics Board Member Elizabeth Floegel Resigns

On August 5, 2025, Elizabeth Floegel resigned from the Board of Directors of NeoGenomics, Inc., effective immediately. Her resignation was not due to any disagreements with the company’s operations, policies, or practices.

The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.

NeoGenomics Earnings Call: Growth Amid Challenges

NeoGenomics Inc. recently held its earnings call, revealing a mixed sentiment among investors and analysts. While the company reported strong clinical revenue growth and impressive performance in Next-Generation Sequencing (NGS), these achievements were tempered by significant declines in pharma services revenue, delays in product launches, and ongoing legal and market challenges. The overall sentiment was cautious as the company focuses on addressing these issues and realigning its strategy for future growth.

NeoGenomics Reports Revenue Growth Amid Rising Losses

NeoGenomics, Inc. is a prominent cancer diagnostics company that specializes in cancer genetics testing and information services, providing a comprehensive range of oncology-focused testing solutions to medical professionals and institutions across the United States and the United Kingdom.